Compare Quest Diagnostics Inc (DGX) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NIO Inc. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while NIO Inc. trades at $3.58 (market cap $8.62B). The key difference: Quest Diagnostics Inc is far larger — about 3× NIO Inc.'s market cap, and Quest Diagnostics Inc pays a 1.49% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and NIO Inc. for 81 Days on average.
| DGX | NIO | |
|---|---|---|
Market Cap | $25.48B | $8.62B |
Volume | 941,866 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $7.42 |
52-Week Low | $173.49 | $3.37 |
Typical Hold Time | 56 Days | 81 Days |
Enterprise Value | $31.23B | $6.52B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
NIO trades at $3.41, down 3.67% today and near its 52-week low of $3.38. The stock shows bearish technical signals with negative moving averages, though recent quarterly earnings have consistently beaten expectations. Revenue growth remains strong at $87.49 billion for 2025, but profitability challenges persist with a net loss of $15.57 billion. The recent Geely battery-swap partnership provides strategic expansion potential while raising questions about near-term profitability.
NIO presents a high-risk opportunity with significant upside potential given the $6.23 consensus price target, but faces substantial execution risks in China's competitive EV market. While analyst sentiment leans bullish with 50% buy ratings, investors must weigh strong revenue growth against persistent losses and negative cash flow trends before considering position entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
